StocksFundsScreenerSectorsWatchlists
UBX

UBX - UNITY Biotechnology Inc Stock Price, Fair Value and News

1.65USD+0.02 (+1.23%)Delayed as of 28 Mar 2024, 10:04 am ET

Market Summary

UBX
USD1.65+0.02
Delayedas of 28 Mar 2024, 10:04 am
1.23%

UBX Stock Price

View Fullscreen

UBX RSI Chart

UBX Valuation

Market Cap

23.8M

Price/Earnings (Trailing)

-0.45

Price/Sales (Trailing)

114.61

Price/Free Cashflow

-0.68

UBX Price/Sales (Trailing)

UBX Profitability

Return on Equity

-145.08%

Return on Assets

-75.83%

Free Cashflow Yield

-147.74%

UBX Fundamentals

UBX Revenue

Revenue (TTM)

236.0K

UBX Earnings

Earnings (TTM)

-52.5M

Earnings Growth (Yr)

-11.53%

Earnings Growth (Qtr)

-25.27%

Breaking Down UBX Revenue

52 Week Range

1.463.82
(Low)(High)

Last 7 days

4.7%

Last 30 days

-19.5%

Last 90 days

-1.9%

Trailing 12 Months

-58.5%

How does UBX drawdown profile look like?

UBX Financial Health

Current Ratio

5.74

UBX Investor Care

Shares Dilution (1Y)

3.02%

Diluted EPS (TTM)

-3.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20223.6M2.5M1.4M236.0K
20210004.8M
20170001.4M

Tracking the Latest Insider Buys and Sells of UNITY Biotechnology Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 26, 2024
nguyen alexander hieu
acquired
-
-
20,000
chief legal officer
Feb 02, 2024
ghosh anirvan
sold
-1,162
1.71
-680
chief executive officer
Jan 30, 2024
ghosh anirvan
sold
-2,022
1.71
-1,183
chief executive officer
Nov 02, 2023
ghosh anirvan
sold
-1,077
1.83
-589
chief executive officer
Oct 30, 2023
ghosh anirvan
sold
-1,945
1.9
-1,024
chief executive officer
Sep 14, 2023
ghosh anirvan
sold
-3,077
2.47
-1,246
chief executive officer
Aug 02, 2023
ghosh anirvan
sold
-1,708
2.94
-581
chief executive officer
Jul 31, 2023
ghosh anirvan
sold
-2,917
2.86
-1,020
chief executive officer
Jun 26, 2023
ghosh anirvan
sold
-3,766
3.2
-1,177
chief executive officer
Jun 14, 2023
ghosh anirvan
sold
-4,108
3.39
-1,212
chief executive officer

1–10 of 50

Which funds bought or sold UBX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
unchanged
-
-263,953
1,083,890
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
66.45
13,890
54,918
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
93,945
93,945
-%
Feb 14, 2024
AllSquare Wealth Management LLC
unchanged
-
-26.00
106
-%
Feb 14, 2024
Royal Bank of Canada
reduced
-75.91
-3,000
1,000
-%
Feb 14, 2024
Ameritas Investment Partners, Inc.
unchanged
-
-47.00
193
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
-23,500
96,500
-%
Feb 14, 2024
UBS OCONNOR LLC
reduced
-48.24
-250,881
178,911
0.01%

1–10 of 41

Are Funds Buying or Selling UBX?

Are funds buying UBX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own UBX
No. of Funds

Unveiling UNITY Biotechnology Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
alyeska investment group, l.p.
9.99%
1,676,818
SC 13G/A
May 10, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2023
alyeska investment group, l.p.
9.99%
1,419,000
SC 13G
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Oct 11, 2022
fmr llc
-
0
SC 13G/A
Sep 12, 2022
fmr llc
-
0
SC 13G/A
Feb 14, 2022
venrock associates vii, l.p.
4.6%
2,680,039
SC 13G/A
Feb 11, 2022
arch venture fund vii, l.p.
17.4%
10,048,181
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Jul 01, 2021
baillie gifford & co
4.52%
2,479,068
SC 13G/A

Recent SEC filings of UNITY Biotechnology Inc

View All Filings
Date Filed Form Type Document
Mar 27, 2024
4
Insider Trading
Mar 20, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 05, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading

Peers (Alternatives to UNITY Biotechnology Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

UNITY Biotechnology Inc News

Latest updates
InvestorsObserver15 Mar 202402:27 pm
CNN13 Feb 202412:28 pm

UNITY Biotechnology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q42017Q4
Revenue---236---
Operating Expenses6.0%13,91713,13012,49418,26714,68214,169
  S&GA Expenses7.3%5,2804,9224,9415,8065,1042,578
  R&D Expenses5.2%8,6378,2087,55312,4619,57911,591
Interest Expenses14.3%990866894808826-
Net Income-3.4%-14,168-13,708-13,137-18,915-10,693-12,544
Net Income Margin-517.6%-253.93*-41.12*-23.58*-17.52*-12.69*-
Free Cashflow4.6%-10,403-10,904-14,846-14,972-5,067-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-31.4%69.0010111412413698.00112125126136148156175165158151142154161181195
  Current Assets-32.1%50.0073.0086.0097.0010368.0081.0091.0085.0088.00102101136124115129126141152173180
    Cash Equivalents-58.8%8.0019.0023.0013.0023.0019.0016.0034.0022.0013.0027.0018.0050.0041.0027.0039.0038.0025.0036.0016.0029.00
  Net PPE-26.0%5.007.007.008.008.009.009.0010.0011.0011.0012.0013.0014.0014.0015.0017.005.006.006.006.006.00
Liabilities-35.9%33.0052.0056.0058.0058.0058.0062.0065.0068.0070.0068.0073.0077.0052.0052.0031.0027.0027.0014.0021.0015.00
  Current Liabilities-61.2%9.0022.0022.0020.0017.0016.0018.0017.0013.0013.0010.0014.0017.0016.0015.0017.0014.0015.0011.0017.0012.00
  Long Term Debt-100.0%-4.008.0011.0013.0013.0015.0018.0024.0025.0025.0025.0024.00--------
    LT Debt, Current-100.0%-14.0013.009.007.007.005.003.001.00------------
    LT Debt, Non Current-100.0%-4.008.0011.0013.0013.0015.0018.0024.0025.0025.0025.0024.00--------
Shareholder's Equity-26.7%36.0049.0059.0067.0079.0040.0051.0060.0058.0066.0080.0083.0098.00112105121115127147161180
  Retained Earnings-3.2%-498-483-470-459-445-432-418-400-389-372-355-339-319-292-273-245-227-205-182-163-141
  Additional Paid-In Capital0.4%535533530527525472470460447439435422418405379367343333329325322
Shares Outstanding0.1%15.0015.0014.0014.0010.007.007.006.005.005.005.005.00---------
Float------33.00---202---326---277---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations36.0%-7,101-11,099-11,300-10,366-10,856-14,835-14,972-5,060-11,525-13,375-15,100-16,714-17,219-19,327-25,073-15,721-16,800-19,304-20,596-12,806-13,885
  Share Based Compensation-13.0%2,0552,3612,2702,2592,2102,2502,6602,9413,0862,7822,7442,7003,6924,1043,3173,0883,8231,9441,9972,5162,717
Cashflow From Investing44.6%14,2499,85421,278-191-36,23017,693-5,8179,07817,152-97914,062-14,575-6,60812,3093,666-4,47225,0817,28440,060-9898,628
Cashflow From Financing-600.1%-18,377-2,62527416750,2201384,3306,8622,9001,01910,06451532,85921,5088,99320,8685,407881282297-11.00

UBX Income Statement

2023-09-30
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]    
Licensing revenue - related party   $ 236
Operating expenses:    
Research and development$ 4,901$ 8,208$ 17,26628,222
General and administrative4,4284,92214,68115,669
Impairment of long-lived assets5,602 5,6020
Total operating expenses14,93113,13037,54943,891
Loss from operations(14,931)(13,130)(37,549)(43,655)
Interest income6893292,349416
Interest expense(470)(866)(2,451)(2,568)
Other income (expense), net(577)(41)(711)49
Net loss(15,289)(13,708)(38,362)(45,758)
Other comprehensive (loss) gain    
Unrealized gain (loss) on marketable debt securities81(88)196(231)
Comprehensive loss$ (15,208)$ (13,796)$ (38,166)$ (45,989)
Net loss per share, basic$ (1.05)$ (1.36)$ (2.66)$ (5.77)
Net loss per share, diluted$ (1.05)$ (1.36)$ (2.66)$ (5.77)
Weighted-average number of shares used in computing net loss per share, basic[1]14,598,21810,072,07714,446,6727,928,729
Weighted-average number of shares used in computing net loss per share, diluted[1]14,598,21810,072,07714,446,6727,928,729
[1]The Company effected a reverse stock split of its outstanding shares of common stock on October 19, 2022 where every ten shares of its common stock issued and outstanding was converted into one share of common stock. Any fractional post-split shares as a result of the reverse split were rounded down to the nearest whole post-split share. Shareholders of the Company previously authorized the Board of Directors to approve a reverse stock split at the annual meeting on October 18, 2022. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the reverse stock split on a retroactive basis in all periods presented.

UBX Balance Sheet

2023-09-30
Condensed Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 7,876$ 12,736[1]
Short-term marketable securities38,06382,059[1]
Prepaid expenses and other current assets3,5991,740[1]
Total current assets49,53896,535[1]
Property and equipment, net5,3147,825[1]
Operating lease right-of-use assets13,52219,042[1]
Long-term restricted cash896896[1]
Other long-term assets052[1]
Total assets69,270124,350[1]
Current liabilities:  
Accounts payable1,1491,790[1]
Accrued compensation2,2263,020[1]
Accrued and other current liabilities5,2585,334[1]
Current portion of long-term debt09,476[1]
Total current liabilities8,63319,620[1]
Operating lease liability, net of current portion24,43126,991[1]
Long-term debt, net of current portion010,891[1]
Total liabilities33,06457,502[1]
Commitments and contingencies (Note 8)
Stockholders’ equity:  
Convertible preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding00[1]
Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 14,614,890 and 14,215,302 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively[2]11[1]
Additional paid-in capital534,570527,049[1]
Accumulated other comprehensive loss(55)(251)[1]
Accumulated deficit(498,310)(459,951)[1]
Total stockholders’ equity36,20666,848[1]
Total liabilities and stockholders’ equity$ 69,270$ 124,350[1]
[1]The balance sheet as of December 31, 2022 is derived from the audited financial statements as of that date.
[2]The Company effected a reverse stock split of its outstanding shares of common stock on October 19, 2022 where every ten shares of its common stock issued and outstanding was converted into one share of common stock. Any fractional post-split shares as a result of the reverse split were rounded down to the nearest whole post-split share. Shareholders of the Company previously authorized the Board of Directors to approve a reverse stock split at the annual meeting on October 18, 2022. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the reverse stock split on a retroactive basis in all periods presented.
UBX
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEunitybiotechnology.com
 EMPLOYEES22

UNITY Biotechnology Inc Frequently Asked Questions


What is the ticker symbol for UNITY Biotechnology Inc? What does UBX stand for in stocks?

UBX is the stock ticker symbol of UNITY Biotechnology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of UNITY Biotechnology Inc (UBX)?

As of Wed Mar 27 2024, market cap of UNITY Biotechnology Inc is 23.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of UBX stock?

You can check UBX's fair value in chart for subscribers.

What is the fair value of UBX stock?

You can check UBX's fair value in chart for subscribers. The fair value of UNITY Biotechnology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of UNITY Biotechnology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for UBX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is UNITY Biotechnology Inc a good stock to buy?

The fair value guage provides a quick view whether UBX is over valued or under valued. Whether UNITY Biotechnology Inc is cheap or expensive depends on the assumptions which impact UNITY Biotechnology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UBX.

What is UNITY Biotechnology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, UBX's PE ratio (Price to Earnings) is -0.45 and Price to Sales (PS) ratio is 114.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UBX PE ratio will change depending on the future growth rate expectations of investors.